Indonesia Energy Corporation Limited vs Viatris Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.74 (market cap $43.24M), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 463.2× Indonesia Energy Corporation Limited's market cap, and Viatris Inc pays a 2.75% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Viatris Inc for 57 Days on average.
| INDO | VTRS | |
|---|---|---|
Market Cap | $43.24M | $20.03B |
Volume | 116,953 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $6.74 | $18.27 |
52-Week Low | $2.49 | $9.74 |
Typical Hold Time | 24 Days | 57 Days |
Enterprise Value | $38.18M | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Indonesia Energy Corporation (INDO) trades at $2.81, up 1.44% with a bearish technical outlook despite 100% analyst buy ratings. The oil and gas explorer shows severe financial stress with negative margins (-152.7% net income margin) and consistent quarterly losses, though recent K-29 well discoveries offer operational catalysts. Cash flow remains dependent on financing activities as operations burn $5.43M annually.
High-risk speculative opportunity exists given the disconnect between negative fundamentals and optimistic analyst sentiment. Success hinges on new well production scaling revenue to achieve profitability. Key risks include execution delays, sustained cash burn, and oil price volatility that could threaten liquidity without additional financing.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →